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In lung cancer progression, p53 mutations are more
often observed in invasive tumors than in noninva-
sive tumors, suggesting that p53 is involved in tumor
invasion andmetastasis. To understand the nature of
p53 function as a tumor suppressor, it is crucial to
elucidate the detailed mechanism of the alteration
in epithelial cells that follow oncogenic KRAS activa-
tion and p53 inactivation. Here, we report that KRAS
activation induces epithelial-mesenchymal transi-
tion and that p53 inactivation is required for cell
motility and invasiveness. Furthermore, TSPAN2,
a transmembrane protein, is responsible for cell
motility and invasiveness elicited by p53 inactivation.
TSPAN2 is highly expressed in p53-mutated lung
cancer cells, and high expression of TSPAN2 is asso-
ciated with the poor prognosis of lung adenocari-
nomas. TSPAN2 knockdown suppresses metastasis
to the lungs and liver, enabling prolonged survival.
TSPAN2 enhances cell motility and invasiveness by
assisting CD44 in scavenging intracellular reactive
oxygen species.
INTRODUCTION
The tumor suppressor protein p53 responds to various stimuli,
including genotoxic stresses and oncogenic activation, and
activates the transcription of numerous target genes involved
in cell-cycle arrest and apoptosis to prevent tumor cell
growth (Bourdon et al., 2003; Lane and Levine, 2010; Oren,2003). Thus, one of the functions of p53 is to induce irrevers-
ible cell growth (Zuckerman et al., 2009). On the other hand,
clinicopathological studies of lung specimens have implied
that p53 is also involved in tumor invasion and metastasis
because p53 inactivation is more often observed in invasive
tumors than in noninvasive tumors in lung cancer progression
(Iwakawa et al., 2008; Robles and Harris, 2010). Indeed,
several lines of recent evidence have shown that p53 regulates
invasion and cell motility, which are associated with aggres-
sive and metastatic phenotypes of cancer cells (Aylon and
Oren, 2011; Gadea et al., 2007; Muller et al., 2011; Vinot
et al., 2008).
Lung adenocarcinomas (ADCs) have been thought to arise
from the accumulation of various genetic alterations, including
oncogenic activation, such as KRAS and epidermal growth
factor receptor (EGF-R) and tumor suppressor inactivation,
such as p16INK4A and p53 in small airway epithelial cells
(SAECs), which are the putative origin of lung ADCs (Forgacs
et al., 2001; Majidi et al., 2007; Sato et al., 2006). In particular,
the p53 pathway is inactivated in most lung ADCs and
is a key regulator of invasive phenotypic transition (Iwakawa
et al., 2008). Epithelial-mesenchymal transition (EMT) is
regarded as an important event for triggering invasion and
dissemination from primary tumors (Biddle and Mackenzie,
2012). Snail and Twist are known as EMT inducers and p53
inactivation promotes EMT by derepressing Snail expression
and upregulating Twist expression (Kim et al., 2011; Kogan-
Sakin et al., 2011).
Although there are many factors contributing to lung cancer
progression, including invasiveness andmetastasis, the detailed
molecular mechanism of how p53 contributes to lung cancer
progression is unknown. In particular, gene regulation depends
on cellular contents, and it is crucial to identify p53-relatedCell Reports 7, 527–538, April 24, 2014 ª2014 The Authors 527
Figure 1. Immortalized SAECs Are Intact in the p53 Pathway
(A) Cell growth curve of parental SAECs is shown. Cells were grown in SAGM and maintained by passaging at 1–2 dilution and changing medium every 3 days.
(B) Expression levels of transduced proteins in parental SAECs are shown by immunoblot analysis. GAPDH is shown as a loading control.
(C) Telomerase activity is detectable in SAECs infected with CycD1, CDK4, and TERT lentiviruses but not parental SAECs.
(D) Cell growth curve of immortalized SAECs is shown. Cells were grown in SAGM and maintained by passaging at 1–8 dilution.
(E) Immortalized SAECs are exhibited lung epithelial features. Expression of lung epithelial markers, SP-C and CCSP, in primary and immortalized SAECs (SAEC
CCT) but not HeLa cells (negative control) was detected by immunofluorescence.
(F) p53 is activated in immortalized SAECs in response to actinomycin D (ActD) and Nutlin-3a. Cells were incubated in the absence or presence of 5 nM ActD or
10 mM Nutlin-3a for 16 hr, and these cell lysates were subjected to immunoblotting. GAPDH is shown as a loading control.factors using an appropriate cell system. In this study, we estab-
lished a system to elucidate the detailed mechanism of the alter-
ation of epithelial cells, the main origin of solid tumors, such as
lung cancers, following KRAS activation and p53 inactivation.
Using this system, we found that KRAS activation was linked
to EMT and that p53 inactivation enhanced cell motility and
invasiveness. Furthermore, we identified a key molecule dere-
pressed by p53 inactivation, as a factor responsible for the
promotion of cell motility and invasiveness in lung ADCs. Intrigu-
ingly, p53 knockdown increases invasiveness and cell motility in
various lung cancer cells through the derepression of TSPAN2
belonging to a family of four transmembrane-spanning protein.
TSPAN2 expression was associated with the p53 mutation sta-
tus and poor prognosis in lung ADCs, and the suppression of
TSPAN2 expression inhibited cell motility and invasion, conse-
quently preventing metastasis to the lungs. Finally, we eluci-
dated that TSPAN2 scavenged intracellular reactive oxygen
species through the CD44-mediated pathway to enhance cell
motility and invasiveness.528 Cell Reports 7, 527–538, April 24, 2014 ª2014 The AuthorsRESULTS
KRAS Activation Induces EMT, and p53 Inactivation
Enhances Cell Invasion and Motility in SAECs
SAECs were able to grow in conditioned medium for a while, but
cells stopped growing and exhibited a senescent phenotype
through the upregulation of p16INK4A, a cell-cycle inhibitor, after
five to six population doublings (PDs) (Figures 1A and 1B). Slight
increases of p53 and p16INK4A may be due to oxidative stress
during cell culture (Rayess et al., 2012). Therefore, primary
SAECs were immortalized by the expression of a mutant form
of CDK4 devoid of binding ability to p16INK4A, CyclinD1, and
TERT to bypass p16INK4A-mediated senescence and prevent
telomere erosion. Immunoblotting analyses showed the expres-
sions of CDK4, CyclinD1, and p16INK4A in SAECs (Figure 1B).
We also confirmed TERT activity in immortalized cell lines using
the telomeric repeat amplification protocol (TRAP) assay (Fig-
ure 1C), and immortalization of SAECs was successful, because
cells continued to grow even after 144 PDs (Figure 1D). Next, we
Figure 2. p53 Inactivation, but Not KRAS, which Induces an Epithelial-Mesenchymal Transition-like Phenotype, Enhances Cell Invasion and
Motility in Immortalized Small Airway Epithelial Cells
(A) A mimetic system with genetic alternations in human epithelial cells during lung carcinogenesis is represented.
(B and C) p53 knockdown is enhanced motility (B) and invasiveness (C) in immortalized SAECs. Cells were transfected with the indicated siRNAs, and in vitro cell
migration and invasion assays using cell-culture inserts were performed, as described in Experimental Procedures. Relative activities to the control siRNA are
shown.
(D) Expression levels in immortalized SAECs infected with indicated viruses are shown. Cells were infected with either control viruses or KRASV12 expression
viruses, followed by infection with either control viruses or p53-directed short-hairpin double-stranded RNAs (shp53) expression viruses. Expression levels of
indicated proteins in these cell lysates were determined by immunoblotting.
(E) Morphological change of immortalized SAECs by expression of KRASV12 but not p53 knockdown. Stable transformants in (D) were observed under a dif-
ferential interference contrast microscope.
(F) Induction of EMT-like property by KRASV12 expression but not p53 knockdown. Expression levels of EMT-related genes altered by KRASV12 expression were
determined by RT-PCR.
(G) KRASV12 expression did not influence invasive activity in immortalized SAECs. Invaded cells were stained with Diff-Quick solution, and stained cells were
counted under a light microscope. Relative activities to the control cells are shown.
Error bars indicate SD of three independent measurements.confirmed that these cells maintained the characteristics of pri-
mary SAECs as assayed by immunofluorescence for surfactant
protein C (SP-C) and Clara cell secretory protein (CCSP), which
are differentiation and functional markers for alveolar epithelial
type II cells (AEC2) andClara cells, respectively (Lundin and Dris-
coll, 2013). As shown in Figure 1E, SAECs, but not HeLa (nega-
tive control), were expressed SP-C and CCSP, suggesting that
they exhibit typical characteristics of human lung epithelial cells
and are likely to be a heterogeneous population containing
AEC2, Clara cells, and bronchioalveolar stem cells (BASCs)
(Lundin and Driscoll, 2013). To test whether the p53 pathway is
still intact, immortalized cells were treated with DNA-damaging
agents. Accumulation of p53 was detected, and p21waf1 andMdm2, p53 target genes, were upregulated in response to
DNA damage, such as actinomycin D (ActD) and Nutlin-3a, a
p53 activator, suggesting that the p53 system is functional in
immortalized SAECs (Figure 1F).
Under these conditions, we examined the effect of oncogenic
KRAS activation and p53 inactivation on cell motility, invasive-
ness, and EMT, which are thought to be associated with tumor
progression (Figure 2A). p53 expression was downregulated by
p53-directed small-interfering double-stranded RNAs (si-p53#1
and si-p53#2) in order to elucidate the detailed pathological
role of p53 in the regulation of invasion and motility during lung
cancer progression. Invasiveness and motility are enhanced
by p53 knockdown, as measured by assays using cell-cultureCell Reports 7, 527–538, April 24, 2014 ª2014 The Authors 529
inserts (8 mm pore) coated with or without Matrigel (Figures 2B
and 2C). It has recently been reported that p53 inactivation pro-
motes EMT by derepressing Snail expression and upregulating
Twist expression, inducers of EMT (Kim et al., 2011; Kogan-
Sakin et al., 2011); therefore, we tested whether p53 inactivation
elicits EMT in immortalized SAECs. SAECs were infected with
either control viruses or KRASV12 expression viruses, followed
by infection with either control viruses or p53-directed short-
hairpin double-stranded RNAs (shp53) expression viruses, and
expressions of KRAS and p53 in stable transformants were
confirmed by immunoblot analysis (Figure 2D). For this experi-
ment, KRASV12 expression was maintained at low level because
overexpression of oncogenic KRAS induced cell growth arrest
such as oncogene-induced cellular senescence. Even if ectopic
KRAS expression is only slightly higher than endogenous
expression, activation of downstream MAPK pathways but not
AKT pathways in SAECs expressing oncogenic KRAS could be
detected, as assayed by immunoblotting (Figure 2D). Under
these conditions, p53 knockdown did not induce an EMT-like
phenotype (Figure 2E, cf. panel 1 to panel 3), as judged
by morphological changes, downregulation of E-cadherin, an
epithelial marker and upregulation of mesenchymal markers
including N-cadherin and Vimentin (Figure 2F, cf. lane 1 to
lane 3). These data suggest that p53 seems not to regulate
EMT, at least under our conditions, using immortalized cells
of normal lung epithelial cell origin. KRAS gene mutations have
often occurred in atypical adenomatous hyperplasia (AAH) and
bronchioloalveolar carcinoma (BAC) observed in the early event
of lung pathogenesis (Iwakawa et al., 2008; Kitamura and Oku-
dela, 2010); therefore, we assessed the effect of KRAS activation
on EMT in SAECs. Interestingly, the expression of KRASV12 in
SAECs gives rise to the EMT-like phenotype, as determined by
cell morphology (Figure 2E, compare panels 1 and 3 to panels
2 and 4) and expression of EMT markers (Figure 2F, compare
lanes 1 and 3 to lanes 2 and 4). More intriguingly, KRASV12
expression did not enhance invasive and motile activities (Fig-
ure 2G, compare panels 1 and 2 to panels 3 and 4), as seen in
p53-depleted SAECs, suggesting that the EMT-like phenome-
non does not appear to link to invasiveness and motility and
that alternative p53 pathways contribute to the aggressiveness.
Identification of p53-Regulated Genes Encoding
Cell-Surface Proteins Responsible for Cell Invasion
and Motility
To elucidate the mechanism by which p53 loss enhances inva-
sive and motile activities in SAECs, we performed comprehen-
sive expression profiling analyses between p53 knockdown
and control cells using GeneChip Human Genome U133 plus
2.0 arrays. These experiments showed that 29 genes were upre-
gulated (fold induction, >2) and 28 genes were downregulated
(fold reduction, <0.5) in p53-knockdown SAECs (Figures 3A).
Among them, nine genes (CLIC4, IL6ST, TMEM87B, TMEM64,
FZD2, EMP2, CHRNA1, TSPAN2, and CA9) encoding a cell-
surface protein derepressed by p53 knockdown were selected,
because membrane-spanning cell-surface proteins have
emerged as key regulators in invasion, motility, and metastasis,
and, as a future perspective, antibodies and nucleic acid ap-
tamers against such proteins may be utilized as targets for can-530 Cell Reports 7, 527–538, April 24, 2014 ª2014 The Authorscer therapy (Deonarain et al., 2009; Dua et al., 2011; Haeuw et al.,
2011; Hemler, 2008). Among these nine genes, TSPAN2 was an
uncharacterized factor, and the high expression level of TSPAN2
was significantly associated with poor prognosis, although a sig-
nificant association of high expression of other genes with poor
prognosis was not observed in the same samples (Figures 3B
and S1; Table S1A). We further assessed which genes are actu-
ally derepressed by p53 inactivation. Expression level of
TSPAN2 was significantly associated with the p53 mutation sta-
tus in lung cancer cell lines (Iwakawa et al., 2010), as measured
by quantitative real-time PCR (Figure 3C; Table S1B), and
TSPAN2 expression in lung cancer cells harboring deletion,
null, and missense mutations of p53 was significantly higher
than that in cells harboring wild-type p53 (wild-type p53 versus
deletion and null p53, p = 0.0268; wild-type p53 versusmissense
p53, p = 0.00876; Figure 3C). In addition, TSPAN2 expression
in lung cancer cells harboring missense mutations of p53 was
moderately, but not significantly, higher than that in cells
harboring deletion and null mutations of p53 (deletion and null
p53 versus missense p53, p = 0.095; Figure 3C).
We also confirmed that TSPAN2 was derepressed by p53
knockdown in SAECs using quantitative real-time PCR (Fig-
ure 3D) and immunoblotting with anti-TSPAN2 antibody (Fig-
ure 3E). In addition, treatment of cells with Nutlin-3a decreased
TSPAN2 expression (Figure S2A), and the decrease was in a
p53-dependent manner (Figure S2A). However, p53 knockdown
had little or no effect on TSPAN2 expression in MCF7 cells, a
human mammary carcinoma cell line (Figure S2B), although
TSPAN2 expression in SAECs treated with si-p53 significantly
increased compared with that in control cells (Figure S2C), sug-
gesting that p53 regulates the expression level of TSPAN2 with
some tissue specificity. In addition, knockdown of mutant p53
in EBC1 cells decreased TSPAN2 expression (Figure S2D), sug-
gesting that mutated p53 has some potential to activate TSPAN2
expression. Furthermore, the high expression level of TSPAN2
was significantly related to p53 mutation in patients with lung
ADCs (p = 0.005; Figure 3F). Thus, we speculate that the expres-
sion level of TSPAN2 in cells is maintained at a low level by the
expression of wild-type p53 and focused on TSPAN2 in later
analyses.
TSPAN2 Regulates p53-Mediated Cell Invasion and
Motility
TSPAN2 is categorized as a four transmembrane-spanning pro-
tein belonging to the tetraspanin family, somemembers of which
have been reported to regulate tumor progression (Hemler,
2008; Romanska and Berditchevski, 2011; Wang et al., 2011).
To address whether TSPAN2 contributes to invasion andmotility
by p53 knockdown, TSPAN2 was downregulated in p53-
depleted SAECs. In vitro migration and Matrigel invasion assays
showed that TSPAN2 knockdown inhibited invasive and motile
activities activated by p53 knockdown, suggesting that TSPAN2
is a factor responsible for invasiveness and motility associated
with p53 inactivation (Figures 4A–4C). To address whether
TSPAN2 is also involved in invasiveness and motility in other
established lung cancer cell lines, we used EBC1 cells highly
expressing TSPAN2, which expresses a mutant p53. As ex-
pected, cell motility and invasion in EBC1 cells were significantly
Figure 3. TSPAN2 Is Identified as aGeneDerepressed by p53Depletion in SAECs, and Its High Expression Is Associatedwith Poor Prognosis
in Patients with Lung ADCs
(A) Genes altered by p53 knockdown in SAECs are indicated. The heatmap shows 29 genes upregulated by p53 knockdown (fold induction, >2) and 28 genes
downregulated by p53 knockdown (fold reduction, <0.5).
(B) High expression of TSPAN2 is associated with poor prognosis. Association of expression level of TSPAN2 with the prognosis of NSCLC patients in expression
profile studies from KLM and MSK was obtained from the PrognoScan database (Mizuno et al., 2009).
(C) Expression level of TSPAN2 in various human lung cancer cell lines harboring mutant p53 (deletion, null, and missense mutations) is higher than that in cells
harboring wild-type p53 (Student’s t test, p < 0.05). Human lung cancer cell lines used for this assay were listed in Table S1B.
(D and E) p53 knockdown derepressed expression of TSPAN2. Cells were transfected with the indicated siRNAs and total RNA prepared from these cells was
subjected to quantitative real-time PCR (D) and immunoblotting (E). Clathrin heavy chain (CHC) is shown as a loading control.
(F) Comparison of expression of TSPAN2 in patient’s samples with or without p53 mutations (unpaired t test, p < 0.05).
Error bars indicate SD of three independent measurements. See also Figures S1 and S2 and Table S1.suppressed by TSPAN2 knockdown (Figures 4D–4F). We next
tested the effect of TSPAN2 knockdown on H441 cells, a human
lung cancer cell line; T98G cells, a human glioblastoma cell line;
and DLD-1 cells, a human colorectal cancer cell line, which were
all harboring mutant p53. TSPAN2 knockdown decreased cell
motility in all cell lines tested, suggesting that TSPAN2 is involved
in the aggressiveness of various cancerous cell types including
lung, glioblastoma, and colorectal cancer (Figures S3A–S3C).
We also examined whether TSPAN2 is contributed to cell motility
driven by transforming growth factor (TGF)-b1. Treatment of
A549 cells, a human lung cancer cell line, with TGF-b1 increased
cell motility, but TSPAN2 knockdown had little effect on cell
motility driven by TGF-b1 (Figure S3D). Themigratory rate in cells
stably expressing small hairpin RNA (shRNA) against TSPAN2
was slower than that of control cells (Figures 4G and 4H); in
contrast, forced expression of FLAG-HA-His-tagged TSPAN2
(TSPAN2-FHH) in SAECs (Figure 4I) enhanced migratory activity(Figure 4J) and invasive activity (Figures 4K and 4L); in contrast,
FLAG-HA-His-tagged CD82 (CD82-FHH), which is known as a
metastasis suppressor belonging to the tetraspanin family (Tsai
and Weissman, 2011), did not enhance invasiveness (Figures
4K and 4L). Taken together, TSPAN2 has the ability to promote
invasiveness and motility in lung cancers.
TSPAN2 Knockdown Suppresses Tumor Metastasis to
Lung
We next assessed whether TSPAN2 affected invasive and met-
astatic activities into the lungs in vivo. SAECs were infected with
lentiviruses for the expression of large T and small T antigens,
which inactivate substantial p53 function (Tiemann et al., 1995)
compared to p53 knockdown, followed by oncogenic KRASV12
expression to generate SAECLSK possessing tumorigenicity in
immunodeficient NOD-scid, interleukin (IL)-2Rg-null (NOG)
mice (Nakamura and Suemizu, 2008) (Figure S4A). QuantitativeCell Reports 7, 527–538, April 24, 2014 ª2014 The Authors 531
Figure 4. TSPAN2 Regulates p53-Mediated Cell Invasion and Motility
(A) Efficiency of TSPAN2 knockdown in SAEC was determined by quantitative real-time PCR.
(B and C) Inhibition of p53-inactivation-mediated motility (B) and invasiveness (C) in immortalized SAECs by TSPAN2 knockdown.
(D) Efficiency of TSPAN2 knockdown in EBC1 cells was determined by quantitative real-time PCR.
(E and F) Inhibition of motility (E) and invasiveness (F) in EBC1 cells.
(G and H) Attenuation of migratory rate in SAECs by TSPAN2 knockdown. The cell movements for ten cells were analyzed using AxioVision Version 4.8 Cell
Tracking software (G). Velocity of the cell movements was calculated by the ratio of cumulated distance to elapsed time (H).
(I) Expression level of TSPAN2 in SAECs infected with lentiviruses with or without TSPAN2-FHH.
(J) Cell motility in SAECs stably expressing TSPAN2-FHH.
(K and L) Invasive activity in SAECs stably expressing TSPAN2-FHH or CD82-FHH using 3D-Matrigel invasion assay. Photograph of invading cells under light
microscope (K). Quantification of invading cells (L). Error bars indicate SD of three independent measurements.
See also Figure S3.real-time PCR experiments revealed that large T and small T
antigens as well as p53 knockdown resulted in upregulation
of TSPAN2 (Figure S4B), indicating that TSPAN2 expression
increases in SAECs expressing large T and small T antigens
compared with those expressing wild-type p53. Under these
conditions, SAECLSK stably expressed shRNA against TSPAN2
(SAECLSK-pL-shTSPAN2), the expression level of TSPAN2 was
measured using RT-PCR (Figures 5A and S4C), and metastatic
activity was assessed in NOGmice. For real-time imaging in vivo,
a luciferase gene was introduced into SAECLSK-pL-shTSPAN2,
and these cells were inoculated into the tail vein of mice. Under
in vitro culture conditions, TSPAN2 knockdown had little or no ef-
fect on cell proliferation (Figure S4D) or anchorage-independent
growth in soft agar (Figure S4E), whereas TSPAN2 knockdown
abrogated cell motility (Figure 5B) and invasive activity (Fig-
ure 5C) in vitro, and metastatic activity to lung tissues, as visual-532 Cell Reports 7, 527–538, April 24, 2014 ª2014 The Authorsized by in vivo imaging using an IVIS system (Figure 5D). Most
mice inoculated with TSPAN2-depleted cells were still alive
at 48 days postinoculation, although all mice inoculated with
SAECLSK control cells had died by this time point (Figure 5E). His-
tological analyses using hematoxylin and eosin staining showed
that control cells invaded lung organs to a much greater extent
and exhibited liver metastases (Figure 5F); in contrast,
TSPAN2-depleted cells (#1 and #2) slightly invaded the lungs
but had little metastatic activity to other organs (Figures 5G
and 5H).
TSPAN2 Knockdown Increased the Production of
Reactive Oxygen Species through CD44 to Inhibit
Invasive and Motile Activities
What is themechanism by which TSPAN2 controls invasiveness,
motility, and metastasis? To investigate this mechanism, we
Figure 5. TSPAN2 Knockdown Suppresses Tumor Metastasis to Lung
(A) Efficiency of TSPAN2 knockdown in SAECLSK. Cells were transfected with the indicated siRNAs, and the expression level of TSPAN2 was determined by
quantitative real-time PCR.
(B and C) TSPAN2 knockdown in SAECLSK decreases cell motility (B) and invasive activity (C).
(D) Suppression of metastatic activity of SAECLSK by stable expression of shTSPAN2 in vivo. SAECLSK were infected with lentiviruses encoding luciferase and
inoculated intravenously in NOG mice. Time kinetics of lung metastasis in mice was measured using a real-time in vivo imaging system (left). Tumor growth in
lungs was quantified using Living Image software (right) (n = 5, *p < 0.01 versus vector control).
(E) Survival curve of mice that had been transduced with SAECLSK with or without the expression of shTSPAN2.
(F–H) Hematoxylin and eosin staining of paraffin sections in metastasized lung and liver tissues in mice inoculated with control cells (F), shTSPAN2#1-expressing
cells (G), or shTSPAN2#2-expressing cells (H). Metastasized cancers are indicated with arrows.
Scale bars, 200 mm (right panels) and 500 mm (left panels). Error bars indicate SD of three independent measurements. See also Figure S4.explored binding partners for TSPAN2. In the immunoprecipita-
tion assay, we used CD82 to compare these binding partners.
TSPAN2-FHH or CD82-FHH was stably expressed in cells and
sequentially immunoprecipitated with anti-FLAG and anti-HA
antibodies. Proteomic databases for proteins belonging to
the tetraspanin family predict that several proteins, including
CD44, MT1-MMP, ADAM10, and integrins, are candidates as
binding partners (Le Naour et al., 2006; Andre´ et al., 2006; Xu
et al., 2009). Therefore, the eluates from anti-FLAG antibody-
immobilized beads were subjected to immunoblotting with
anti-CD44, anti-MT1-MMP, anti-ADAM10, and anti-integrin
antibodies because these proteins are involved in cell motility
and invasion in cancers. Immunoblot analyses showed that
TSPAN2-FHH bound to all proteins tested; in contrast, CD82-
FHH did not (Figure 6A), suggesting that TSPAN2 contributes
to various signaling pathways, consistent with the fact thatseveral tetraspanin proteins function as integrators for various
signals, including TGF-b and EGFR pathways (Murayama
et al., 2008; Sadej et al., 2010). To identify the key signaling
pathway for invasiveness and motility, we first tested the effect
of TSPAN2 expression on CD44 shedding because MT1-MMP
and ADAM10 are known to cleave CD44, and the cleaved cyto-
plasmic domain of CD44 enters the cytoplasm to promote inva-
sion (Nakamura et al., 2004; Stamenkovic and Yu, 2009); how-
ever, TSPAN2 knockdown had little or no effect on ectodomain
cleavage of CD44 (Figure S5A). In addition, forced expression
of TSPAN2 had little or no effect on CD44 cleavage (Figure S5B).
Next, as shown in recent reports, mutant p53 promoted invasion
via integrin trafficking (Muller et al., 2009, 2011). Therefore,
we next assessed whether the expression of TSPAN2 influenced
the recycling of integrin alpha2beta1, which binds to TSPAN2;
however, recycling activity was not affected by TSPAN2Cell Reports 7, 527–538, April 24, 2014 ª2014 The Authors 533
Figure 6. TSPAN2 Regulates the Production of Reactive Oxygen Species in Cooperation with CD44 for the Inhibition of Cell Motility and
Invasion
(A) Identification of binding partners with TSPAN2. Lysates from cells stably expressing TSPAN2-FHH or CD82-FHH were sequentially immunoprecipitated with
anti-FLAG and anti-HA antibodies, followed by immunoblotting with the indicated antibodies.
(B and C) Inhibition of the p38MAPK pathway, but not JNK and ERK pathways, enhances invasive activity in TSPAN2-depleted SAECLSK. Invasive activity of
SAECLSK stably expressing shTSPAN2 was measured using 3D-Matrigel invasion assay. Photograph of invading cells under light microscopy (B). Quantification
of invading cells (C).
(D) Increased ROS level by CD44 knockdown. Knockdown efficiency of si-CD44 was determined by immunoblotting (left panel). Clathrin heavy chain (CHC) is
shown as a loading control. Cells were incubated with 10 mMDCFH-DA for 10min at 37C and treated with or without 500 mMH2O2 for the indicated periods. The
fluorescence was measured using a fluorescence spectrophotometer and relative fluorescent values to the control are shown (right panel).
(E) Decreased invasive activity of SAECLSK by CD44 knockdown. Cells were transfected with si-CD44 and analyzed by cell invasion assays using cell-culture
inserts.
(F) Increased ROS in SAECLSK by TSPAN2 knockdown. Cells were transfected with si-TSPAN2 and used for measurement of intracellular ROS.
(G) Cooperation of TSPAN2 with CD44. Suppressive effect of intracellular ROS production by TSPAN2 expression in SAECLSK was abolished by CD44
knockdown. Cells with or without ectopic expression of TSPAN2 were transfected with si-CD44 and fluorescence in cell lysates from cells treated with DCFH-DA
in the absence () or presence (+) of 500 mM H2O2 for 60 min was measured.
(H and I) Low redox potential advantages of the invasive phenotype in SAECLSK. Cells were embedded in Matrigel in the absence or presence of NAC or BSO at
the indicated concentrations, observed 10 days after incubation under a light microscope (H) and invading cells were quantified (I). Error bars indicate SD of three
independent measurements.
See also Figures S5 and S6.expression (Figure S5C), suggesting that TSPAN2 regulates
alternative pathways to promote motility and invasion. To eluci-
date the signaling pathways by which TSPAN2 enhances tumor
invasiveness, we next examined the effect of specific inhibitors
of signaling pathways, including the JNK pathway, ERK/MEK
pathway, and p38MAPK pathway, on invasiveness in TSPAN2-
depleted SAECs because these pathways have been implicated
in lung tumor malignancy (Kim and Choi, 2010; Malemud, 2007).
The 3D Matrigel-invasion assay showed significant enhance-
ment of invasiveness in TSPAN2-depleted SAECLSK by treat-534 Cell Reports 7, 527–538, April 24, 2014 ª2014 The Authorsment with the p38MAPK inhibitor but not JNK andMEK inhibitors
(Figures 6B and 6C). p38MAPK is activated by reactive oxygen
species (ROS) (Zhang et al., 2003), and the CD44-mediated
pathway is known to be involved in the defense against oxidative
stress (Ishimoto et al., 2011; Zhao et al., 2008). Based on our
data that TSPAN2 regulates the p38MAPK pathway and inter-
acts with CD44, we examined whether TSPAN2 is involved in
CD44-mediated ROS production in SAECLSK. CD44 knockdown
exhibits increased ROS production following H2O2 treatment
(Figure 6D) and a decreased invasive phenotype (Figure 6E),
Figure 7. Proposed Model for the Mecha-
nism of Invasiveness and Motility during
Lung Tumor Progression
Model for the mechanism of invasiveness and
motility elicited by p53 inactivation during lung
tumor progression. In cells harboring wild-type p53,
the expression level of TSPAN2 is maintained by
p53; however, in p53 mutant cells, TSPAN2 is
derepressed and binds CD44 to suppress ROS
production. Reduced ROS by TSPAN2 induction
enhances cell motility, invasion, and metastasis.suggesting that CD44 has a ROS-scavenging function in lung
cancer cells to promote invasiveness and cell motility. We next
examined the effect of TSPAN2 on ROS production following
H2O2 treatment of SAEC
LSK. Intriguingly, ROS production in
TSPAN2-depleted cells treated with H2O2 was significantly
higher than in control cells (Figure 6F), and decreased ROS pro-
duction by forced expression of TSPAN2 was canceled by CD44
knockdown (Figure 6G). To further address the relationship be-
tween TSPAN2 and CD44 on the mechanism for ROS produc-
tion, we first examined whether endogenous TSPAN2 interacts
with CD44 by immunoprecipitation with anti-TSPAN2 antibody.
Immunoblot analysis of immunoprecipitates showed that the
interaction of TSPAN2 with CD44 was detected (Figure S6A).
Next, to determine which region of TSPAN2 is required for the
interaction with CD44, we constructed various expression vec-
tors for deletion mutants of TSPAN2 (Figure S6B) and deter-
mined that the region designated as the cytoplasmic C-terminal
tail in TSPAN2 protein (TSPAN2DC-tail) was a major binding site
to CD44 (Figure S6C). Migration and invasion assays using cell-
culture inserts showed that the expression of TSPAN2DC-tail
(Figure S6D) did not enhance cell motility (Figure S6E) or invasion
(Figure S6F) compared with wild-type TSPAN2. Furthermore,
TSPAN2DC-tail had little or no ability to reduce intracellular
ROS production (Figure S6G). Thus, these data suggest that
the interaction of TSPAN2 with CD44 is crucial for maintenance
of the intracellular ROS level. Indeed, this idea is supported by
the fact that p53 knockdown decreases the oxidation level in
SAECs (Figure S6H). Finally, we tested the effect of intracellular
redox modulators on invasiveness into SAECLSK. We first deter-
mined appropriate concentrations of N-acetyl-cysteine (NAC),
an antioxidant agent, and buthionine sulfoximine (BSO), a pro-
ducer of oxidative stress in cells, by measurement of intracel-
lular ROS activity. The level of intracellular ROS production
was decreased by treating cells with NAC at a concentration of
2 mM, as efficiently as that of cells ectopically expressing
TSPAN2 (Figure S6I). On the other hand, the level of intracellular
ROS production was increased by treating cells with BSO at
a concentration of 0.5 mM, as efficiently as that of TSPAN2-Cell Reports 7, 527–depleted cells (Figure S6J). Under these
conditions, treatment of cells with NAC
enhanced the invasive phenotype; in
contrast, oxidative stresses elicited by
BSO significantly decreased invasive
activity (Figures 6H and 6I). These data
demonstrate that TSPAN2 derepressedby p53 inactivation enhances cell motility and invasiveness
through CD44 to scavenge intracellular ROS (Figure 7).
DISCUSSION
Based on clinical studies of lung cancer, p53mutations are more
often observed in invasive tumors than in noninvasive tumors
(Iwakawa et al., 2008; Robles and Harris, 2010), implying that
p53 regulates cancerous cell invasion and metastasis. Several
critical factors and mechanisms for these phenomena have
been identified, and several lines of recent evidence have shown
that p53 regulates invasion and cell motility, which are associ-
ated with aggressive and metastatic phenotypes of cancer cells
(Muller et al., 2011). In the present study, we established a
mimetic systemwith genetic alternations in epithelial cells during
lung carcinogenesis and found that KRAS activation was linked
to EMT and that KRAS activation-induced EMT was not suffi-
cient to give rise to invasiveness andmotility, rather p53 inactiva-
tion, by which EMT-like phenotype was not induced, is the main
cause of enhanced invasiveness and motility. These results are
consistent with the fact that p53 inactivates during the transition
from noninvasive to invasive tumors in lung ADCs. The relation-
ship between EMT and tumor progression, including invasive-
ness and motility, is still controversial (Biddle and Mackenzie,
2012; Geiger and Peeper, 2009; Yilmaz and Christofori, 2009).
Our present data support that p53 inactivation, but not EMT, is
essential for invasiveness andmotility, though these data cannot
exclude the possibility that p53 inactivation cooperatively con-
trols invasiveness and motility with EMT.
TSPAN2 derepressed by p53 inactivation is involved in lung
cancer progression. Our data demonstrate that TSPAN2 expres-
sion is significantly higher in lung ADCs possessing mutant p53
than in those bearing wild-type p53 and that the basal level of
p53 is sufficient to repress the expression of TSPAN2 mRNA.
In addition, based on gene expression profiling databases
in HLM and MSK (both are recognized as most reliable data-
bases for gene expression profiling) (Shedden et al., 2008),
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prognosis in lung ADCs. Genes derepressed by p53 inactivation,
such as MDR1 (Johnson et al., 2001), CD44 (Godar et al., 2008),
and TCTP (Amson et al., 2012), have so far been identified, and
we found TSPAN2 to be a derepressed gene by p53 loss under
unstressed conditions. Unfortunately, the mechanism of tran-
scriptional derepression of TSPAN2 by p53 inactivation is not
simple, and we did not clarify that TSPAN2 is a direct p53 target
gene, although a reporter assay using the TSPAN2 promoter re-
gion (2,000–+36) and ChIP analysis by scanning the proximal
TSPAN2 promoter region between 2,000 and +1,000 using
various specific primers were carried out (data not shown).
One reason is that p53may inhibit the recruitment of some coac-
tivators of TSPAN2 expression by binding p53 to these coactiva-
tors (Bo¨hlig and Rother, 2011). Alternatively, TSPAN2 expression
may be regulated by interferencewith the distal enhancer activity
of p53 because the expressions of many genes suppressed by
p53 in embryonic stem (ES) cells are affected by cis element
far from promoter regions (Li et al., 2012). Although further inves-
tigation will be necessary to elucidate how p53 regulates
TSPAN2 expression, we have demonstrated that TSPAN2 is a
factor responsible for human lung cancer cell motility and inva-
sion. In the future, antibodies and nucleic acid aptamers against
TSPAN2 may be utilized as drugs for lung cancer therapy.
TSPAN2 is a four transmembrane-spanning protein belonging
to the tetraspanin family and binds to variousmembrane proteins
to modulate intracellular signaling (Hemler, 2008; Wang et al.,
2011). Here, we found intriguing data that TSPAN2 is involved
in lung cancer progression, including invasiveness, motility,
and metastasis, and binds CD44 to suppress intracellular
oxidative stresses. It has been reported that p53 controls the
redox-oxidation state through transcription-dependent and -in-
dependent regulation of pro-oxidant and antioxidant enzymes
(Liu et al., 2008). However, this regulation is presumably depen-
dent on cellular contexts, and, if p53 inactivation occurs in lung
tumor progression, lung tumor cells may evade oxidative stress,
because stem cells protect against oxidative damage to main-
tain the cell population (Kobayashi and Suda, 2012). This idea
is supported by the fact that p53 knockdown decreased the
oxidation level in our system using human lung epithelial cells
and that treatment of cells with NAC, an antioxidant agent,
enhanced the invasive phenotype; in contrast, oxidative stresses
elicited by BSO decreased invasion. According to previous re-
ports (Ishimoto et al., 2011), the variant form of CD44 (CD44v)
functions to scavenge oxidative stress through the interaction
with cysteine transporter (xCT) on the transmembrane to stabi-
lize xCT, and subsequently increases intracellular glutathione
to maintain cancer-initiating cell-like properties in gastrointes-
tinal cancers (Ishimoto et al., 2011); however, it has recently
been reported that the standard form of CD44 (CD44s) is
involved in the clinical outcome of patients with lung ADCs (Ko
et al., 2011). Therefore, CD44s may also function in oxidative
defense through the interaction with TSPAN2 because TSPAN2
knockdown increased the intracellular oxidative level, enhance-
ment of the redox state elicited by TSPAN2 overexpression was
abolished by CD44 knockdown, and TSPAN2 lacking CD44-
binding capacity had no ability to suppress intracellular ROS
production. What kind of CD44 isoforms TSPAN2 works with
and how the interaction of CD44 with TSPAN2 transduces sig-536 Cell Reports 7, 527–538, April 24, 2014 ª2014 The Authorsnals for oxidative defense will need further investigation, but
TSPAN2 will be a potential target for cancer therapy by prevent-
ing the interaction with CD44. Because the decrease of intracel-
lular ROS via theCD44 systemcontributed to themaintenance of
cancer-initiating cell-like properties in gastrointestinal cancers,
TSPAN2 may play a role in the acquisition of cancer-initiating
cell-like properties in lung ADCs. Whether TSPAN2 is required
for the maintenance of cancer-initiating cell-like properties will
be the next significant question.
In conclusion, TSPAN2 derepressed by p53 inactivation is
linked tocancer invasivenessandmetastasis in lungADCsanden-
hances intracellular redox potential in cooperation with CD44 to
protect tumor cells from oxidative damage. Moreover, EMT-like
features are insufficient for showing invasive and motile pheno-
types, and the p53-TSPAN2 axis is a key pathway to the aggres-
siveness of lung ADCs. Our data presented here will provide
new insights into a relevant mechanism by which p53 inactivation
promotes tumor invasion andmotility during lung carcinogenesis.
EXPERIMENTAL PROCEDURES
For more details, see Supplemental Information.
Establishment of Immortalized SAECs
Plasmid Construction
cDNAs encoding human TSPAN2 and CD82 were amplified by PCR, and DNA
fragments were subcloned into pLentiV5/DEST (Invitrogen). DNA fragments
encoding KRASV12 were amplified by PCR using cDNA pools from H441 cells
and subcloned into pBABE-puro (Addgene). For deletion constructs of
TSPAN2, two-step PCR-based targeted mutagenesis was used (Armengaud
and Jouanneau, 1993). Details about constructs and primer sequences can
be found in Supplemental Experimental Procedures.
RNAi Experiments
Cells were transfected with the small interfering RNAs (siRNAs) using Lipofect-
amine 2000 or Lipofectamine RNAi MAX (Invitrogen), according to the manu-
facturer’s instructions. Details about siRNA sequences and shRNA constructs
can be found in Supplemental Experimental Procedures.
In Vitro Cell Migration and Invasion Assays
Migration and invasion assays were performed using 24-well transwell cham-
bers with polyethylene terephthalate filters of 8 mm pore size with or without
Matrigel (Becton Dickinson), according to the manufacturer’s instructions.
Details about these methodologies can be found in Supplemental Experi-
mental Procedures.
RNA Isolation, Quantitative Real-Time PCR, and RT-PCR
Total RNA from cells was isolated using an RNeasy kit (QIAGEN) and reverse-
transcribed with Super Script II First-Strand Synthesis System for RT-PCR kit
(Invitrogen). Quantitative real-time RT-PCR was carried out in a ABI Prism
7900HT Sequence Detection system (Applied Biosystems). Semiquantitative
RT-PCR was carried out in a PCR thermal cycler (MJ Research), and the
PCR products were subjected to electrophoresis on 2% agarose gels. Details
about these methodologies and primer sequences can be found in Supple-
mental Experimental Procedures.
Microarray Experiment
Total RNA was purified using an RNeasy kit (QIAGEN) and subjected to micro-
array experiment using a GeneChip Human Genome U133 plus 2.0 arrays
(Affymetrix) according to the manufacturer’s instructions. Details about these
methodologies can be found in Supplemental Experimental Procedures.
Expression Data in Patients’ Samples
The relationship of TSPAN2 expression and the p53 mutation status
was analyzed using a data set of patients’ lung cancer samples (n = 41: p53
mutation, 18; no p53 mutation, 23) (Ding et al., 2008), and information about
this data set is available at Oncomine (https://www.oncomine.org/).
Immunoblot Analysis and Immunoprecipitation
Immunoblotting and immunoprecipitation were performed as described previ-
ously (Enari et al., 2006; Ohata et al., 2013), and FLAG-HA-His-tagged TSPAN2
and CD82 in cells were sequentially immunoprecipitated with anti-FLAG
antibody (M2)-conjugated beads (Sigma-Aldrich) and anti-HA antibody-
conjugated beads (Roche). Endogenous TSPAN2 was immnoprecipitated
with anti-TSPAN2 (Avnova) antibody-conjugated Protein G Sepharose 4B
(GE Healthcare) and normal IgG was used as a control. Details about these
methodologies can be found in Supplemental Experimental Procedures.
Three-Dimensional Matrigel Invasion Assay
Ninety-six transwell plates were used for the 3D Matrigel invasion assay. Cells
(13 103) were suspended in a mixture of culture medium andMatrigel (Becton
Dickinson) (1:1, v/v) and layered onto solidified Matrigel. For 6–8 days after
culturing, colonies were observed under a light microscope or confocal
microscope, representative pictures of each experiment were taken, and cell
numbers morphologically exhibiting the invasive outgrowth phenotype were
counted.
Time-Lapse Motility Assay
Cells (23 105) were plated in 6-well plates 1 day before assay, and cell images
under a light microscope were obtained every 15 min for 16 hr. Velocity of
the cell movements was analyzed using AxioVision Version 4.8 Cell tracking
software (Carl Zeiss).
Measurement of Cellular Reactive Oxygen Species
Cells (53 104) in suspension were incubated with 10 mMDCFH-DA (CELL BIO-
LABS) for 10 min at 37C, washed with PBS, and treated with or without
500 mM H2O2. The fluorescence corresponding to the cellular ROS level was
monitored in a black plate using a fluorescence spectrophotometer at excita-
tion of 480 nm and emission of 530 nm.
In Vivo Metastatic Assay
Cells stably expressing a luciferase gene were inoculated intravenously
through the tail vein of 7-week-old female NOD-scid, IL-2Rg-null (NOG)
mice. NOG mice were obtained from the Central Institute for Experimental
Animals (Kawasaki, Japan). Tumor growth in the lungs was monitored using
the IVIS imaging system (Xenogen), and tissue samples were stained with
hematoxylin and eosin. Details about these methodologies can be found in
Supplemental Experimental Procedures. All animal care followed theGuideline
for Animal Experiments at the National Cancer Center and was approved by
the institutional committee for Ethics of Animal Experimentation.
Statistical Analysis
Data are represented as the means ± SD of three or more independent exper-
iments. Statistical analysis was performed by Student’s t test and unpaired
t test at significance levels of p < 0.05.
ACCESSION NUMBERS
The GEO accession number for the row and processed microarray data pre-
sented in this paper is GSE47436.
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Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
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